March 20, 2026 – Abbott introduced that it expects to finish its acquisition of Precise Sciences on Monday, March 23, 2026. The announcement follows the receipt of all regulatory approvals required for the closure.

The transaction permits Abbott to enter and lead the fast-growing most cancers screening and diagnostics segments, serving thousands and thousands of extra individuals. Along with Precise Sciences, Abbott will speed up innovation, broaden entry to life-changing diagnostics and assist extra individuals detect and deal with most cancers at its earliest, most treatable phases.

Precise Sciences is a frontrunner in most cancers screening, precision oncology and genetic testing, serving to to detect most cancers earlier, information therapy choices and monitor for recurrence.

This acquisition strengthens Abbott’s management place and capabilities in diagnostics, positioning the corporate to advance applied sciences which are extra preventative, predictive and personalised. It expands Abbott’s presence in one of many quickest rising areas of healthcare because the incidence of most cancers continues to rise worldwide. It additionally provides new vertical development to Abbott’s already excessive single-digit development expectations, establishing management within the fast-growing $60 billion U.S. most cancers screening and precision oncology diagnostics segments.

Learn extra from Abbott.